Table 1. Comparison of Hepatitis B virus (HBV) mutations described in the literature with those found in the HBV sequence of a patient presenting with acute biochemical hepatitis (patient 1745).

Mutations are relating to chronic HBV with acute reactivation (CHB-AR), acute hepatitis B (AHB) and HBV associated acute on chronic liver failure. Mutations present in >10% of sequences are marked in bold, mutations present in <10% of sequences are not represented.

Gene (Protein)	Site	Polymorphisms reported in the literature	Disease Association and References	Sequencing Methods Used	Genes Sequenced	Genotype studied	Patient 1745 sequence
Precore/ core	1896	G1896A	CHB-AR during cytotoxic chemotherapy or SCT ** 23, 40	Sanger 23 Sanger 40	Basal core promotor + precore 23 Surface, RT ***, precore 40	Not stated C/D	G1896: 66% G1896A: 25%
			Hepatitis B Related Acute-on-Chronic Liver Failure 41	Sanger	Basal core promotor, precore	B/C
			Distinguish CHB-AR from AHB 24, 42	Enzyme linked assays 24 Sanger 42	Specific mutations only: G1896A + A1762T, G1764A 24 Pre-core 42	B/C Not stated
			Comparing CHB with CHB-AR 43	Sanger	Basal core promotor, precore	B/C
			CHB-AR and Fulminant hepatic failure during chemotherapy 26	Sanger	Full length genome	A/B/C
	1899	G1899A	Hepatitis B-Related Acute-on-Chronic Liver Failure 41	Sanger	Basal core promotor, precore	B/C	G1899: 85% G1899A: 14%
			CHB-AR during chemotherapy or SCT 40	Sanger	Surface, RT, precore	C/D
Precore Promoter Regions	1742	G1742A	CHB-AR during chemotherapy 44	Sanger	Basal core promotor, precore	Unknown	G1742: 95%
	1752	A1752G	CHB-AR during chemotherapy 44	Sanger	Basal core promotor, precore	Unknown	A1752: 98%
	1753	T1753V (C/A/G)	Hepatitis B-Related Acute-on-Chronic Liver Failure 41	Sanger	Basal core promotor, precore	B/C	T1753: 99%
			CHB-AR during chemotherapy 44	Sanger	Basal core promotor precore	Unknown
	1754	T1754G	CHB-AR during chemotherapy 44	Sanger	Basal core promotor, precore	Unknown	T1754: 99%
	1762	A1762T	Hepatitis B-Related Acute-on-Chronic Liver Failure 41	Sanger	Basal core promotor, precore	B/C	A1762: 99%
			Distinguish CHB-AR from AHB 24	Enzyme linked assays	Specific mutations only: G1896A + A1762T, G1764A	B/C
			CHB-AR 25	Sanger	Basal core promotor, precore	B/C
			CHB-AR during chemotherapy 44	Sanger	Basal core promotor, precore	Unknown
	1764	G1764A	Hepatitis B-Related Acute-on-Chronic Liver Failure 41	Sanger	Basal core promotor, precore	B/C	G1764: 84% G1764A: 14%
			Distinguish CHB-AR from AHB 24	Enzyme linked assays	Specific mutations only: G1896A + A1762T, G1764A	B/C
			CHB-AR 25	Sanger	Basal core promotor, precore	B/C
			CHB-AR during chemotherapy 44	Sanger	Basal core promotor, precore	Unknown
	1766 1768	C1766T/T1768A double mutation & T1768A alone	Distinguish CHB-AR from AHB 28	Sanger	Surface, basal core promotor, precore, X-gene.	A/C/D	C1766: 97% T1768: 98%
	1799	G1799A/C1799G	CHB-AR during chemotherapy 44	Sanger	Basal core promotor, precore	Unknown	C1799: 98%
Surface Antigen (amino acid locations)	190	V190A	CHB-AR on immunosuppression 45	Sanger	Surface	D	V190A: 97%
	127	T127P	CHB-AR in aHSCT 46	Next generation deep sequencing	Full length genome	A/D/E	T127P: 98%
	118 120 128 133 145 172	T118A P120S/T A128V M133I G145R W172*	Immune escape mutations associated with AHB 36	Ultradeep pyro-sequencing	Surface and RT	A/D	No mutations present

**Stem cell transplant.

*** Reverse transcriptase